Hammerhead ribozyme-mediated knockdown of mRNA for fibrotic growth factors: Transforming growth factor-beta 1 and connective tissue growth factor

8Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Excessive scarring (fibrosis) is a major cause of pathologies in multiple tissues, including lung, liver, kidney, heart, cornea, and skin. The transforming growth factor-β (TGF-β) system has been shown to play a key role in regulating the formation of scar tissue throughout the body. Furthermore, connective tissue growth factor (CTGF) has been shown to mediate most of the fibrotic actions of TGF-β, including stimulation of synthesis of extracellular matrix and differentiation of fibroblasts into myofibroblasts. Currently, no approved drugs selectively and specifically regulate scar formation. Thus, there is a need for a drug that selectively targets the TGF-β cascade at the molecular level and has minimal off-target side effects. This chapter focuses on the design of hammerhead ribozymes, measurement of kinetic activity, and assessment of knockdown mRNAs of TGF-β and CTGF in cell cultures. © 2012 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Robinson, P. M., Blalock, T. D., Yuan, R., Lewin, A. S., & Schultz, G. S. (2012). Hammerhead ribozyme-mediated knockdown of mRNA for fibrotic growth factors: Transforming growth factor-beta 1 and connective tissue growth factor. Methods in Molecular Biology, 820, 117–132. https://doi.org/10.1007/978-1-61779-439-1_8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free